<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00645216</url>
  </required_header>
  <id_info>
    <org_study_id>A5351047</org_study_id>
    <nct_id>NCT00645216</nct_id>
  </id_info>
  <brief_title>Study Examing The Effect of Grapefruit Juice On The Blood And Urine Samples of Study Drug And Its By Product And Safety</brief_title>
  <official_title>A Phase 1, Open Label, Randomized, Fixed Sequence Study To Evaluate The Effect Of Multiple Dose Administration Of Grapefruit Juice On The Multiple Dose Pharmacokinetics Of CP-945,598 In Healthy Overweight And Obese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CP-945,598 is eliminated primarily by enzyme CYP3A. Grapefruit juice may affect the activity
      of CYP3A and alter the amount of CP-945,598 in the blood. This study will therefore compare
      the time course of drug concentrations in the body, safety and tolerability of CP-945,598
      given with or without grapefruit juice in healthy obese/overweight subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of durg and metabolite concentrations in serum from blood sampling collected at various times over 24 hours dosing interval on Day 7 and 21, before dosing on days 5,6, 12, 13, 14, 19 and 20.</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safetey laboratory tests (chemistry, hematology, urinalysis) on Days -1 and 22</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse event monitoring throughout duration of the study</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary 6-Î²-hydroxycortisol:cortisol ratios (CMR) on Days 0 and 21.</measure>
    <time_frame>2 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>CP-945,598 with Grapefruit Juice</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CP-945,598 with Grapefruit Juice</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CP-945,598 alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CP-945,598 alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-945,598</intervention_name>
    <description>Subjects take CP-945,598 alone for 21 days</description>
    <arm_group_label>CP-945,598 alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-945,598</intervention_name>
    <description>Subjects take CP-945,598 from Days 1 to 7, then take CP-945,598 and Grapefruit Juice from Days 8 to 21</description>
    <arm_group_label>CP-945,598 with Grapefruit Juice</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male and female subjects between the ages of 18 and 55 years.

          2. Body Mass Index (BMI) of 27 to 40 kg/m2.

          3. Willing and able to comply with scheduled visits, treatment plan, laboratory tests,
             and other trial procedures.

        Exclusion Criteria:

          -  Non-prescribed use of drugs of abuse/ recreational drugs;

          -  Recent treatment with experimental drugs or herbal experiments;

          -  EKG and blood pressure parameters falling outside of protocol-specified limits;

          -  History of regular alcohol or tobacco use exceeding protocol-specified limits;
             grapefruit juice intolerance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A5351047&amp;StudyName=Study%20Examing%20The%20Effect%20of%20Grapefruit%20Juice%20On%20The%20Blood%20And%20Urine%20Samples%20of%20Study%20Drug%20And%20Its%20By%20Product%20And%20Safety</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2008</study_first_submitted>
  <study_first_submitted_qc>March 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2008</study_first_posted>
  <last_update_submitted>August 6, 2009</last_update_submitted>
  <last_update_submitted_qc>August 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2009</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

